EIT Health selects Droplite, Ninevah and Oxolife for Headstart program Blog Post

Droplite, Ninevah Therapeutics and Oxolife, presents at the Barcelona Science Park, are three of the 16 Spanish startups that will participate in Headstart, the program of the European Institute of Innovation and Technology in Health (EIT Health) that offers support and financing of up to 50,000 € because emerging companies develop their innovations within a unique ecosystem, which gives them access to financing, experts, contacts and knowledge.

 

GalChimia renews the Crédit d’Impôt Recherche (CIR) accreditation Blog Post

GalChimia has renewed the Crédit d’Impôt Recherche (CIR) accreditation from the French Government, which certifies the company as a provider of R&D services in France. The evaluation is related to the company’s participation in the SHIKIFACTORY100 European project, aimed at the production of compounds of high added value in the chemical, food and cosmetic industries. The Galician company has doubled the surface and staff of its R&D&I center at the Barcelona Science Park, which was opened two years ago to accelerate its growth and internationalization strategy. 

 

Droplite opens seed round of 600.000€ to accelerate the manufacturing development of its smart medical diagnostics device Blog Post

Droplite, located in the Parc Cientific de Barcelona (PCB), has recently started the industrial design and manufacturing development of its smart diagnostics device, focused on point of care (POC). The company, that it was born in 2018, as a spinoff of the Institute of Photonics Sciences (ICFO), from the hand of two entrepreneurs: André Guedes (CEO) and Rafael Porcar (CTO), was recognized with the Seal of Excellence by the European Union and with the Innovative SME seal from the Ministry of Science and Innovation.

 

More than 5,000 applications received to participate in the NEUBIAS project coordinated by IRB Barcelona Blog Post

More than 5,000 people have applied to participate in the different training courses offered by the NEUBIAS project, which seeks to expand knowledge in the field of bioimage analysis. Coordinated by IRB Barcelona at PCB, ​​NEUBIAS is the only network of bio-imaging analysts in Europe. It has more than 250 members from 42 countries who share knowledge to improve image analysis technology.

 

Juan Carlos Kaski, new Chief Medical Officer of GlyCardial Diagnostics Blog Post

GlyCardial Diagnostics, based in the Barcelona Science Park, announces the appointment of Prof. Juan Carlos Kaski as Chief Medical Officer. The company –a spinoff of the Research Institute of the Hospital de la Santa Creu i Sant Pau (IR-HSCSP) and the Spanish National Research Council (CSIC), is conducting a clinical trial to validate the performance of Apo J-Glyc as a novel biomarker for the early detection of Myocardial Ischaemia.

 

Nostrum Biodiscovery appoints Ezequiel Mas as its new CEO and embarks on an ambitious expansion plan Blog Post

Nostrum Biodiscovery (NBD) has appointed Ezequiel Mas del Molino as its new CEO to lead a new phase of the company, which is establishing a leading position in the European market as a provider of cutting-edge bioinformatics technologies for drug design and discovery. NBD –a spin-off from the Institute for Research in Biomedicine (IRB Barcelona), the Barcelona Supercomputing Centre (BSC-CNS), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA)– is located at the Barcelona Science Park and the North Campus of the Universitat Politècnica de Catalunya (UPC).

 

The PCB’s scientific community joins the fight against SARS-CoV-2 Blog Post

In response to the health emergency caused by SARS-CoV-2, research centres and biotech companies in the Barcelona Science Park (Parc Científic de Barcelona, PCB) are leading scientific progress in the treatment, vaccination and diagnosis of the novel coronavirus. The PCB will ensure that public centres and businesses can continue with their research projects by providing the resources and services they need.